

FORM PTO-1390 (Modified)  
(REV 11-98)

U.S. DEPARTMENT OF

COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY

DOCKET NUMBER

202617US0PCT

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

**09/763129**INTERNATIONAL APPLICATION NO.  
**PCT/US99/16724**INTERNATIONAL FILING DATE  
**19 August 1999**PRIORITY DATE CLAIMED  
**19 August 1998**

## TITLE OF INVENTION

**ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND FACTOR MONOCLONAL ANTIBODY**

## APPLICANT(S) FOR DO/EO/US

**Man S. CO, et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1.  This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2.  This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.  A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.  A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a.  is transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  has been transmitted by the International Bureau.
  - c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.  A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.  A copy of the International Search Report (PCT/ISA/210).
8.  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a.  are transmitted herewith (required only if not transmitted by the International Bureau).
  - b.  have been transmitted by the International Bureau.
  - c.  have not been made; however, the time limit for making such amendments has NOT expired.
  - d.  have not been made and will not be made.
9.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10.  An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11.  A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

## Items 13 to 20 below concern document(s) or information included:

13.  An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.  An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.  A **FIRST** preliminary amendment.
16.  A **SECOND** or **SUBSEQUENT** preliminary amendment.
17.  A substitute specification.
18.  A change of power of attorney and/or address letter.
19.  Certificate of Mailing by Express Mail
20.  Other items or information:

**Request for Consideration of Documents Cited in International Search Report**  
**Notice of Priority**  
**PCT/IB/304**  
**PCT/IB/308**

U.S. APPLICATION NO. (IF KNOWN SEE 37 CFR 1.492(e)) <b>09/76312</b>	INTERNATIONAL APPLICATION NO. PCT/US99/16724	ATTORNEY'S DOCKET NUMBER 202617US0PCT
--	---	--

21. The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

- |   |            |
|---|------------|
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... | \$1,000.00 |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....  | \$860.00   |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO .....   | \$710.00   |
| <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....   | \$690.00   |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) .....  | \$100.00   |

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$690.00**

Surcharge of **\$130.00** for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)).

20     30

**\$130.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	24 - 20 =	4	x \$18.00	<b>\$72.00</b>
Independent claims	6 - 3 =	3	x \$80.00	<b>\$240.00</b>
Multiple Dependent Claims (check if applicable).			<input checked="" type="checkbox"/>	<b>\$270.00</b>
			<b>TOTAL OF ABOVE CALCULATIONS</b>	<b>= \$1,402.00</b>
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>
			<b>SUBTOTAL</b>	<b>= \$1,402.00</b>
Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)).			<input type="checkbox"/> 20 <input type="checkbox"/> 30 +	<b>\$0.00</b>
			<b>TOTAL NATIONAL FEE</b>	<b>= \$1,402.00</b>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).			<input type="checkbox"/>	<b>\$0.00</b>
			<b>TOTAL FEES ENCLOSED</b>	<b>= \$1,402.00</b>
			Amount to be: refunded	\$
			charged	\$

- A check in the amount of **\$1,402.00** to cover the above fees is enclosed.
- Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:



**22850**

**Surinder Sachar  
Registration No. 34,423**

SIGNATURE

**Norman F. Oblon**

NAME

**24,618**

REGISTRATION NUMBER

**Feb 20 2001**

DATE

09/763129

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Man S. CO, et al.

SERIAL NUMBER: NEW U.S. PCT APPLICATION (based on PCT/US99/16724)


FILED: HEREWITH

FOR: ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND  
FACTOR MONOCLONAL ANTIBODY**REQUEST FOR CONSIDERATION OF DOCUMENTS  
CITED IN INTERNATIONAL SEARCH REPORT**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that applicant(s) request that the Examiner consider the documents cited in the International Search Report according to MPEP §609 and so indicate by a statement in the first Office Action that the information has been considered. When the Form PCT/DO/EO/903 indicates both the search report and copies of the documents are present in the national stage file, there is no requirement for the applicant(s) to submit them (1156 O.G. 91 November 23, 1993).

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon  
Attorney of Record  
Registration No. 24,618  
Surinder Sachar  
Attorney of Record  
Registration No. 34,423



22850

(703) 413-3000  
Fax No. (703) 413-2220  
(OSMMN 1/97)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Man S. CO, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/US99/16724

INTERNATIONAL FILING DATE: 19 August 1999

FOR: ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND  
FACTOR MONOClonAL ANTIBODY**REQUEST FOR PRIORITY UNDER 35 U.S.C. 120  
AND THE INTERNATIONAL CONVENTION**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

<u>COUNTRY</u>	<u>APPLICATION NO.</u>	<u>DAY/MONTH/YEAR</u>
UNITED STATES	09/136,315	19 August 1998

A certified copy of the corresponding Convention application(s) was submitted to the International Bureau in PCT Application No. **PCT/US99/16724**. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

Respectfully submitted,  
OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618  
Surinder Sachar  
Registration No. 34,423

**22850**

(703) 413-3000  
Fax No. (703) 413-2220  
(OSMMN 1/97)